A biotech stock for investors scared to invest in the risky industry
Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart…